Cian Healthcare Limited

BSE:542678 Stock Report

Market Cap: ₹119.0m

Cian Healthcare Valuation

Is 542678 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 542678 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 542678 (₹4.76) is trading below our estimate of fair value (₹77.35)

Significantly Below Fair Value: 542678 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 542678?

Key metric: As 542678 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 542678. This is calculated by dividing 542678's market cap by their current earnings.
What is 542678's PE Ratio?
PE Ratio46.8x
Earnings₹2.54m
Market Cap₹118.98m

Price to Earnings Ratio vs Peers

How does 542678's PE Ratio compare to its peers?

The above table shows the PE ratio for 542678 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average26.8x
543500 Evoq Remedies
43.8xn/a₹198.0m
531210 Colinz Laboratories
32.1xn/a₹161.2m
524752 Decipher Labs
18.9xn/a₹157.8m
531521 Desh Rakshak Aushdhalaya
12.5xn/a₹66.8m
542678 Cian Healthcare
46.8xn/a₹119.0m

Price-To-Earnings vs Peers: 542678 is expensive based on its Price-To-Earnings Ratio (46.8x) compared to the peer average (26.8x).


Price to Earnings Ratio vs Industry

How does 542678's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.7xn/aUS$76.27m
524652 Ind-Swift
2.7xn/aUS$17.25m
No more companies available in this PE range
542678 46.8xIndustry Avg. 36.0xNo. of Companies17PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 542678 is expensive based on its Price-To-Earnings Ratio (46.8x) compared to the Indian Pharmaceuticals industry average (36x).


Price to Earnings Ratio vs Fair Ratio

What is 542678's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

542678 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio46.8x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 542678's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies